^
    Back
    Association details:
    Biomarker:NPM1 mutation + FLT3-TKD mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:Rydapt (midostaurin) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Blood Cancer J
    Title:

    Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort

    Published date:
    05/05/2023
    Excerpt:
    We analyzed the impact of midostaurin in 227 FLT3mut-AML patients included in the AML-12 prospective trial for fit patients ≤70 years (#NCT04687098)….The effect of midostaurin was evident in NPM1mut patients (n = 151), with 2-yr OS of 72% (exposed) vs 50% (naive) patients (p = 0.011)....In conclusion, this study highlights the improved outcome of FLT3mut AML fit patients with the incorporation of midostaurin.
    DOI:
    10.1038/s41408-023-00839-1
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Blood Adv
    Title:

    Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial

    Published date:
    10/13/2020
    Excerpt:
    In this post hoc subgroup analysis from the trial, we evaluated the impact of midostaurin in 163 patients with FLT3-tyrosine kinase domain (TKD) mutations...A trend toward improved disease-free survival was also observed with midostaurin (67.3% vs 53.4%; P = .089), whereas overall survival (OS) was similar in the 2 groups. Patients with AML and NPM1mut/FLT3-TKDmut or core binding factor (CBF)-rearranged/FLT3-TKDmut genotypes had significantly prolonged OS with or without censoring at hematopoietic cell transplantation (HCT), compared with NPM1WT/CBF-negative AMLs.
    DOI:
    10.1182/bloodadvances.2020002904
    Trial ID:
    RATIFY